Experimental drug aims to stop leukemia relapse after transplant
NCT ID NCT04623216
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called sabatolimab, alone or with another drug, in 24 adults and teens with acute myeloid leukemia (AML) who had signs of leftover cancer after a stem cell transplant. The goal was to see if it could prevent the cancer from coming back without causing severe side effects like graft-versus-host disease. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Freiburg im Breisgau, 79106, Germany
-
Novartis Investigative Site
Hamburg, 20246, Germany
-
Novartis Investigative Site
Münster, 48149, Germany
-
Novartis Investigative Site
Bergamo, BG, 24127, Italy
-
Novartis Investigative Site
Bologna, BO, 40138, Italy
-
Novartis Investigative Site
Brescia, BS, 25123, Italy
-
Novartis Investigative Site
Roma, RM, 00165, Italy
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain